All In Biotech

Drug Trial Radar · NCT03070782

Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease

A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) Administered Subcutaneously to Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)

Last checked: Nov 19, 2026Latest source record: Oct 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 286 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

286

Actual

Start

Mar 7, 2017

Primary completion

Jul 26, 2018

Study completion Nov 13, 2018

Sponsor

Lead sponsor
Akcea TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Ionis Pharmaceuticals, Inc.
First posted
Mar 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 681257 and to assess the efficacy of different doses and dosing regimens of ISIS 681257 for reduction of plasma Lipoprotein(a) \[Lp(a)\] levels in participants with hyperlipoproteinemia(a) and established cardiovascular disease (CVD).

Conditions

  • Elevated Lipoprotein(a)
  • Cardiovascular Disease

Interventions

  • ISIS 681257Drug

    ISIS 681257 solution for SC injection.

  • PlaceboDrug

    Sterile normal saline (0.9% NaCl)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Fasting Lipoprotein A [Lp(a)] at the Primary Analysis Time PointTime frame: Baseline and Month 6 (Week 25 for Cohorts A, B and C and Week 27 for Cohorts D and E)
  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 16 weeks post treatment period (up to approximately 1.3 years)
  3. Number of Participants With TEAEs by Maximum SeverityTime frame: Up to 16 weeks post treatment period (up to approximately 1.3 years)
  4. Number of Participants With TEAEs Leading to Study DiscontinuationTime frame: Up to 16 weeks post treatment period (up to approximately 1.3 years)

Locations

32 sites in 5 countries. Site status is shown where the registry gives one.

  • Clinical Site

    Cottonwood, Arizona

  • Clinical Site

    Huntington Beach, California

  • Clinical Site

    La Jolla, California

  • Clinical Site

    Los Angeles, California

  • Clinical Site

    Stanford, California

  • Clinical Site

    Colorado Springs, Colorado

  • Clinical Site

    Boca Raton, Florida

  • Clinical Site

    Jacksonville, Florida

  • Clinical Site

    Kansas City, Kansas

  • Clinical Site

    Baltimore, Maryland

  • Clinical Site

    Boston, Massachusetts

  • Clinical Site

    Cooperstown, New York

  • Clinical Site

    New York, New York

  • Clinical Site

    New York, New York

  • Clinical Site

    Cleveland, Ohio

  • Clinical Site

    Portland, Oregon

  • Clinical Site

    Lancaster, Pennsylvania

  • Clinical Site

    Philadelphia, Pennsylvania

  • Clinical Site

    Providence, Rhode Island

  • Clinical Site

    Houston, Texas

  • Clinical Site

    Falls Church, Virginia

  • Clinical Site

    Milwaukee, Wisconsin

  • Clinical Site

    Ottawa, Canada

  • Clinical Site

    Chicoutimi, Quebec, Canada

  • Clinical Site

    Montreal, Quebec, Canada

  • Clinical Site

    Montreal, Quebec, Canada

  • Clinical Site

    Québec, Quebec, Canada

  • Clinical Site

    Herlev, Denmark

  • Clinical Site

    Viborg, Denmark

  • Clinical Site

    Berlin, Germany

  • Clinical Site

    Cologne, Germany

  • Clinical Site

    Amsterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.